PMID- 16648870
OWN - NLM
STAT- MEDLINE
DCOM- 20070808
LR  - 20230210
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 19
IP  - 7
DP  - 2006 Jul
TI  - Expression of epidermal growth factor receptor in squamous cell carcinomas of the 
      anal canal is independent of gene amplification.
PG  - 942-9
AB  - Immunohistochemical detection of expression of the epidermal growth factor 
      receptor (EGFR) has been utilized to identify eligible patients with solid 
      malignant tumors, including colorectal adenocarcinoma, for monoclonal antibody 
      therapy (eg, cetuximab). The EGFR status in squamous cell carcinoma of the anal 
      canal, an uncommon malignancy traditionally treated with chemoradiation, has not 
      been well investigated. In this study, 38 primary squamous cell carcinomas of the 
      anal canal were immunohistochemically examined for EGFR expression and analyzed 
      by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers. The 
      results showed a variable degree of EGFR expression in 21 (55%) tumors, among 
      which 13 (62%) cases exhibited a 2+ to 3+ staining pattern according to the Dako 
      EGFR phamDx interpretation guide. There were no significant differences among 
      tumors stratified by stage, degree of keratinization, or tissue block storage 
      times. FISH analysis showed that none of the 34 cases with interpretable results 
      had EGFR gene amplification. Increased gene copy numbers due to polysomy 7 were 
      seen in seven of 18 (39%) cases that expressed EGFR protein and four of 16 (25%) 
      cases that did not (P=0.3876). Ten (56%) tumors with positive EGFR staining 
      showed a balanced disomy 7 pattern and one case with monosomy 7 exhibited strong 
      EGFR expression (3+). These results demonstrate that EGFR is overexpressed in 
      more than one-half of the squamous cell carcinomas of the anal canal through 
      mechanisms other than gene amplification. These observations may have important 
      therapeutic implications since EGFR-based targeted therapies have shown promise 
      for other malignant neoplasms.
FAU - Alvarez, Gustavo
AU  - Alvarez G
AD  - Lauren V Ackerman Laboratory of Surgical Pathology, Department of Pathology and 
      Immunology, Washington University School of Medicine, St Louis, MO 63110-1093, 
      USA.
FAU - Perry, Arie
AU  - Perry A
FAU - Tan, Benjamin R
AU  - Tan BR
FAU - Wang, Hanlin L
AU  - Wang HL
LA  - eng
PT  - Journal Article
DEP - 20060428
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anus Neoplasms/genetics/*metabolism/pathology
MH  - Carcinoma, Squamous Cell/genetics/*metabolism/pathology
MH  - ErbB Receptors/genetics/*metabolism
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Up-Regulation
EDAT- 2006/05/02 09:00
MHDA- 2007/08/09 09:00
CRDT- 2006/05/02 09:00
PHST- 2006/05/02 09:00 [pubmed]
PHST- 2007/08/09 09:00 [medline]
PHST- 2006/05/02 09:00 [entrez]
AID - S0893-3952(22)03351-8 [pii]
AID - 10.1038/modpathol.3800608 [doi]
PST - ppublish
SO  - Mod Pathol. 2006 Jul;19(7):942-9. doi: 10.1038/modpathol.3800608. Epub 2006 Apr 
      28.